Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Mouse model of oropharyngeal candidiasis.

Solis NV, Filler SG.

Nat Protoc. 2012 Mar 8;7(4):637-42. doi: 10.1038/nprot.2012.011.

2.

New model of oropharyngeal candidiasis in mice.

Kamai Y, Kubota M, Kamai Y, Hosokawa T, Fukuoka T, Filler SG.

Antimicrob Agents Chemother. 2001 Nov;45(11):3195-7.

3.

A novel bioluminescence mouse model for monitoring oropharyngeal candidiasis in mice.

Mosci P, Pericolini E, Gabrielli E, Kenno S, Perito S, Bistoni F, d'Enfert C, Vecchiarelli A.

Virulence. 2013 Apr 1;4(3):250-4. doi: 10.4161/viru.23529. Epub 2013 Jan 18.

4.

Comparison between bioluminescence imaging technique and CFU count for the study of oropharyngeal candidiasis in mice.

Gabrielli E, Roselletti E, Luciano E, Sabbatini S, Mosci P, Pericolini E.

Cytometry A. 2015 May;87(5):428-36. doi: 10.1002/cyto.a.22666. Epub 2015 Mar 26.

5.

Candida dubliniensis in radiation-induced oropharyngeal candidiasis.

Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):659-62.

PMID:
11402278
6.

The role of yeasts other than Candida albicans in oropharyngeal candidiasis.

Redding SW.

Curr Opin Infect Dis. 2001 Dec;14(6):673-7. Review.

PMID:
11964883
7.

[Experimental oral candidiasis in healthy and immunocompromised BALB/c mice].

Karaman M, Kiray M, Bayrakal V, Bağrıyanık HA, Yılmaz O, Bahar IH.

Mikrobiyol Bul. 2011 Apr;45(2):336-43. Turkish.

PMID:
21644077
8.

Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection.

Wang L, Wang C, Mei H, Shen Y, Lv G, Zeng R, Zhan P, Li D, Liu W.

Mycopathologia. 2016 Feb;181(1-2):29-39. doi: 10.1007/s11046-015-9947-5. Epub 2015 Sep 24.

PMID:
26404163
9.

Animal models of candidiasis.

Clancy CJ, Cheng S, Nguyen MH.

Methods Mol Biol. 2009;499:65-76. doi: 10.1007/978-1-60327-151-6_8.

PMID:
19152040
10.

[Oropharyngeal candidiasis and radiotherapy].

Pinel B, Cassou-Mounat T, Bensadoun RJ.

Cancer Radiother. 2012 May;16(3):222-9. doi: 10.1016/j.canrad.2011.11.004. Epub 2012 Apr 24. Review. French.

PMID:
22537826
11.

Transmission of an azole-resistant isogenic strain of Candida albicans among human immunodeficiency virus-infected family members with oropharyngeal candidiasis.

Müller FM, Kasai M, Francesconi A, Brillante B, Roden M, Peter J, Chanock SJ, Walsh TJ.

J Clin Microbiol. 1999 Oct;37(10):3405-8.

12.

Recent mouse and rat methods for the study of experimental oral candidiasis.

Costa AC, Pereira CA, Junqueira JC, Jorge AO.

Virulence. 2013 Jul 1;4(5):391-9. doi: 10.4161/viru.25199. Epub 2013 May 28. Review.

13.

Protective effects of human saliva on experimental murine oral candidiasis.

Kamagata-Kiyoura Y, Abe S, Yamaguchi H, Nitta T.

J Infect Chemother. 2004 Aug;10(4):253-5.

PMID:
15365870
14.

Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.

Martinez A, Ferrer S, Santos I, Jimenez E, Sparrowe J, Regadera J, De Las Heras FG, Gargallo-Viola D.

Antimicrob Agents Chemother. 2001 Dec;45(12):3304-9.

15.

Contribution of Candida albicans ALS1 to the pathogenesis of experimental oropharyngeal candidiasis.

Kamai Y, Kubota M, Kamai Y, Hosokawa T, Fukuoka T, Filler SG.

Infect Immun. 2002 Sep;70(9):5256-8.

16.

Oropharyngeal candidiasis: a new treatment option.

Klotz SA.

Clin Infect Dis. 2006 Apr 15;42(8):1187-8. Epub 2006 Mar 14. No abstract available.

PMID:
16575740
17.

Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis.

Chiang LY, Sheppard DC, Bruno VM, Mitchell AP, Edwards JE Jr, Filler SG.

Cell Microbiol. 2007 Jan;9(1):233-45. Epub 2006 Aug 24.

PMID:
16939537
18.

A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis.

Alvarez Alvarez ME, Sánchez-Sousa A, Baquero F.

Rev Esp Quimioter. 1998 Dec;11(4):295-315. Review.

PMID:
9990144
19.

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ.

Antimicrob Agents Chemother. 2001 Feb;45(2):471-9.

20.

Beclomethasone dipropionate and oropharyngeal candidiasis.

Milne LJ, Crompton GK.

Br Med J. 1974 Sep 28;3(5934):797-8.

Supplemental Content

Support Center